Skip to main content
Premium Trial:

Request an Annual Quote

We Almost Never Qualify What We Say. Sometimes.

DrugMonkey continues discussing journal choice and impact factors by noting that many scientists are happy to not submit papers to the biggies and stick to their society journals. "There are plenty of well-funded or long-term funded investigators who have published at the society journal level for most of their careers," writes DrugMonkey. The blogger later adds, "There are a LOT of ways to have an independent, productive, well-funded science research careers that do not require you to publish in GlamourMags."

A related discussion centers on the page lengths in such top journals with Jonathan Eisen and Mike the Mad Biologist saying that since Science and Nature papers have to be short and have a narrative, they sometimes leave important details at the wayside. Chad Orzel disagrees; he thinks the restrictions are helpful. "Left to their own devices, academics and scientists are prone to producing really dreadful prose-- convoluted passive-voice sentences chock full of nominalizations and needless qualifications," he writes.


The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.